Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
DiaMedica Therapeutics Inc
DMAC | US
7.16
USD-0.02
-0.28%
DMAC | US
Loading StockChartView...
About DiaMedica Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
17/03/2026
Close
7.16
Open
7.28
High
7.28
Low
7.00
DiaMedica Therapeutics Inc. a clinical stage biopharmaceutical company develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199 a recombinant human tissue kallikrein-1 protein which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis Minnesota.
View LessDMAC | US
Risk
34.5
Sharpe
0.26
Luna's Score
42/100
Recommendation
Sell
Luna says (DMAC | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
38.3%1 month
34.5%3 months
52.7%6 months
61.0%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.43
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
-0.96
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-22.35M
MarketCap
306.07M
MarketCap(USD)
306.07M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-35.18
Short ratio
2.37
Short perc.
0.52
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
1.15
Range1M
2.00
Range3M
2.06
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.18
Price X volume
1.63M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.96 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.43 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 52.70 | 72.80 | Lower Risk |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 306.07M | 3.66B | Emerging |
